Find, compare & contact
Benzphetamine
API Manufacturers & Suppliers
To view suppliers for this material, you need to be logged in first.
This is because of international laws regarding narcotic materials. Furthermore, the contents of this page are only accessible if you are professionaly active in the pharmaceutical industry. In case you are, it is possible to register on our platform, and after your account is approved by our team you will be able to view suppliers and send your request.
Looking for Benzphetamine API 156-08-1?
- Description:
- Here you will find a list of producers, manufacturers and distributors of Benzphetamine. You can filter on certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.
- API | Excipient name:
- Benzphetamine
- Synonyms:
- Benzaphetamine , Benzfetamina , Benzfetamine , Benzfetaminum , Benzphetamine , Benzylamphetamine
- Cas Number:
- 156-08-1
- DrugBank number:
- DB00865
- Unique Ingredient Identifier:
- 0M3S43XK27
About Benzphetamine
Do you want to know more about Benzphetamine? You can find a small explanation about it here. A sympathomimetic agent with properties similar to dextroamphetamine. It is used in the treatment of obesity.
More information such as the structure, indication or toxicity is available on Drugbank, click the ID above.
Benzphetamine is a type of Psychostimulants
Psychostimulants are a specific subcategory of pharmaceutical Active Pharmaceutical Ingredients (APIs) that have gained significant attention in the medical field. These compounds are known for their stimulating effects on the central nervous system, making them valuable for treating various conditions such as attention deficit hyperactivity disorder (ADHD), narcolepsy, and certain cases of depression.
The primary mechanism of action of psychostimulants involves increasing the levels of certain neurotransmitters in the brain, particularly dopamine and norepinephrine. This heightened neurotransmitter activity results in enhanced cognitive functions, improved focus, and increased alertness. The most commonly prescribed psychostimulants include methylphenidate and amphetamines.
Methylphenidate is a well-known psychostimulant that works by blocking the reuptake of dopamine and norepinephrine, thereby increasing their concentrations in the synaptic cleft. This leads to improved concentration and reduced impulsivity in individuals with ADHD. Similarly, amphetamines stimulate the release of these neurotransmitters while also inhibiting their reuptake.
Psychostimulants are typically administered orally in the form of tablets or capsules, allowing for controlled and sustained release of the medication. These APIs undergo rigorous quality control measures to ensure their purity, potency, and safety.
In conclusion, psychostimulants are a specialized class of pharmaceutical APIs that effectively stimulate the central nervous system, leading to improved cognitive functions and reduced symptoms associated with ADHD, narcolepsy, and certain cases of depression. Their mechanisms of action involve enhancing neurotransmitter activity in the brain, particularly dopamine and norepinephrine. By adhering to strict quality control standards, these psychostimulant APIs provide safe and effective treatment options for patients in need.
Benzphetamine (Psychostimulants), classified under Central Nervous System Agents
Central Nervous System (CNS) Agents are a crucial category of pharmaceutical Active Pharmaceutical Ingredients (APIs) that specifically target the central nervous system. The CNS encompasses the brain and spinal cord, playing a vital role in regulating and controlling various bodily functions, including cognition, movement, emotions, and sensory perception. These agents are designed to interact with specific receptors, enzymes, or ion channels within the CNS to modulate neural activity and restore normal functioning.
CNS agents comprise a diverse range of pharmaceutical APIs, including analgesics, anesthetics, antipsychotics, sedatives, hypnotics, anti-epileptics, and antidepressants. Each subcategory addresses distinct neurological disorders and conditions. For instance, analgesics alleviate pain by targeting receptors in the brain and spinal cord, while antipsychotics are employed to manage psychosis symptoms in mental illnesses such as schizophrenia.
The development of CNS agents involves rigorous research, molecular modeling, and extensive clinical trials to ensure safety, efficacy, and specific target engagement. Pharmaceutical companies invest significant resources in identifying novel drug targets, synthesizing new compounds, and optimizing their pharmacological properties. These agents undergo rigorous regulatory evaluations and must adhere to stringent quality standards and guidelines.
Given the prevalence of CNS disorders globally, the market demand for effective CNS agents is substantial. The development of innovative CNS APIs not only improves patient outcomes but also provides valuable commercial opportunities for pharmaceutical companies. Continued advancements in CNS agent research and development hold the promise of groundbreaking therapies that can improve the quality of life for individuals affected by neurological conditions.
